Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Mats Brune, MD PhD, Thomas L. Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Josee Hebert, MD, Martin Höglund, MD PhD, Ain Kaare, MD, Vladimir Lazarevic, MD PhD, Malin Nicklasson, MSc, Kari Remes, MD PhD, David Ritchie, MBChB, PhD FRACP, FRCPA, Mitchell Sabloff, MD, Ruth Spearing, MD, Alexandros Spyridonidis, MD PhD, Jeffrey Szer, MBBS, Per Ljungman, MD PhD

Blood (2018) 132 (Supplement 1): 205.

https://doi.org/10.1182/blood-2018-99-110260

Published: 2018

Journal Articles

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Thomas L Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Tobias Gedde-Dahl, MD PhD, Vladimir Lj Lazarevic, MD PhD, Kari Remes, MD PhD, David Ritchie, MD PhD, Mitchell Sabloff, MD, Alexandros Spyridonidis, MD PhD, Per Ljungman, Mats Brune, MD

Blood (2017) 130 (Supplement 1): 4557.

https://doi.org/10.1182/blood.V130.Suppl_1.4557.4557

Published: 2017

Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Mats L. Brune, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Donna E. Hogge, MD, John Catalano, MD, Elisabeth Wallhult, RN, Bo I. Nilsson, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Stephane Allard, MD, Edward A. Stadtmauer, MD, Kristoffer Hellstrand, MD

Blood (2007) 110 (11): 1846.

https://doi.org/10.1182/blood.V110.11.1846.1846

Published: 2007

Journal Articles

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Elisabeth Wallhult, RN, John Whisnant, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Dileep Bhagwat, PhD, Kristoffer Hellstrand, MD, Bo I. Nilsson, MD, Mats L. Brune, MD

Blood (2007) 110 (11): 4381.

https://doi.org/10.1182/blood.V110.11.4381.4381

Published: 2007

Journal Articles

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Mats Brune, Sylvie Castaigne, John Catalano, Kurt Gehlsen, Anthony D. Ho, Wolf-Karsten Hofmann, Donna E. Hogge, Bo Nilsson, Reuven Or, Ana I. Romero, Jacob M. Rowe, Bengt Simonsson, Ruth Spearing, Edward A. Stadtmauer, Jeff Szer, Elisabeth Wallhult, Kristoffer Hellstrand

Blood (2006) 108 (1): 88–96.

https://doi.org/10.1182/blood-2005-10-4073

Published: 2006

Includes: Supplemental data

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

NARROW

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only